CLINICAL TRIALS RECOVER NORMALITY AFTER THE SANITARY CRISIS
Source: www.farmaindustria.es
Within the terrible pandemic that plagues the world there has been some good news, such as the demonstration of Spain’s leadership in clinical research. The strength and collaboration of years ago between the Spanish Medicines Agency (Aemps), researchers, centers, patients and promoting pharmaceutical companies has been clearly demonstrated, which has resulted in the country progressing to become an international benchmark in clinical research. The best test? In just three months, Spain has become the first European country and fourth in the world by number of clinical trials against the coronavirus, up to a hundred today.
This good work in biomedical research has been reflected during the pandemic also in clinical trials for other pathologies not related to SARS-CoV-2 (80% of these studies are driven by the pharmaceutical industry). The commitment and collaboration of all the public and private agents dedicated to this valuable task have made it possible that in no case have patients who participate in clinical trials been left without their treatment and that, without ending the virus and always guaranteeing safety of patients, the situation in this field has begun to normalize.
Despite the fact that the coronavirus has hit Spain more than other countries of the European Union, the process to resume the usual rhythm in clinical research is taking place in the same way as in other States and we can already speak of a recovery almost total activity, always depending on the characteristics and situation of each center.
In this sense, the Spanish Registry of Clinical Trials (REEC) reveals that in the first semester of the year the Aemps has authorized nearly 400 clinical trials for pathologies other than coronavirus, which shows signs of interest by the agents involved in the clinical research in Spain for not stopping medical progress.
